Predictive value of neutrophil-lymphocyte ratio in preoperative neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma

Kai XIONG; He XIAO; Jijun ZHENG; Wei XIE; Yunfei YE; Ge WANG

doi:10.16016/j.1000-5404.202008047

您当前的位置：

首页 >

文章列表页 >

Predictive value of neutrophil-lymphocyte ratio in preoperative neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma

Clinical Medicine | 更新时间：2026-01-09

- Predictive value of neutrophil-lymphocyte ratio in preoperative neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma
- Journal of Third Military Medical University Vol. 43, Issue 2, Pages: 168-174(2021)
- 作者机构：
  
  400042 重庆，陆军军医大学(第三军医大学)大坪医院肿瘤中心
- 作者简介：
- 基金信息：
- DOI：10.16016/j.1000-5404.202008047
  CLC： R181.32;R446.113;R735.1
- Received：06 August 2020，
  
  Revised：2020-10-31，
  
  Published：30 January 2021
- 稿件说明：
移动端阅览
Kai XIONG, He XIAO, Jijun ZHENG, et al. Predictive value of neutrophil-lymphocyte ratio in preoperative neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma[J]. Journal of Third Military Medical University, 2021, 43(2): 168-174.
DOI：

Kai XIONG, He XIAO, Jijun ZHENG, et al. Predictive value of neutrophil-lymphocyte ratio in preoperative neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma[J]. Journal of Third Military Medical University, 2021, 43(2): 168-174. DOI： 10.16016/j.1000-5404.202008047.

摘要

目的

探究中性粒细胞-淋巴细胞比值(neutrophil-lymphocyte ratio

NLR)在预测食管鳞状细胞癌(esophageal squamous cell carcinoma

ESCC)术前新辅助放化疗效果中的价值。

方法

选择本中心2016年1月至2020年6月行术前新辅助放化疗ESCC患者104例，收集行新辅助放化疗前3 d的血常规检验结果，主要包括:中性粒细胞计数、淋巴细胞计数、单核细胞计数、血小板计数，并计算NLR、血小板-淋巴细胞比值(platelet lymphocyte ratio

PLR)、淋巴细胞-单核细胞比值(lymphocyte monocyte ratio

LMR)。利用新辅助治疗前后碘水造影、胸部增强CT记录判断肿瘤退缩等级，并对所有患者的生存状况进行随访。采用Mann-Whitney

检验分析组间连续变量差异。受试者工作曲线(receiver operator characteristic curve

ROC)分析NLR对新辅助缓解预测效能和最佳截断值。χ

检验分析不同组间临床特征构成比差异。Logistic回归分析新辅助缓解独立预测因素。Cox回归分析总生存(overall survival

OS)独立预后因素。

结果

新辅助放化疗后达到完全缓解(complete remi

ssion

CR)、部分缓解(partial remission

PR)、稳定(stable disease

SD)和进展(progression disease

PD)的患者分别有0例、38例、54例和12例。治疗前血液NLR是ESCC新辅助放化疗缓解的独立预测因素(

=0.404，95%

: 0.208~0.787

=0.008)。ROC曲线分析显示NLR对新辅助放化疗后达到缓解有中等预测效能(AUC=0.737

95%

: 0.631~0.844

0.001)。根据Youden指数得出最佳截断值为2.77，对应敏感度和特异性分别为0.712和0.737。多因素Cox回归表明只有新辅助治疗后行手术治疗是OS独立预后因素(

=0.258

95%

: 0.068~0.983

=0.047)。

结论

新辅助治疗前ESCC患者血液NLR可能作为治疗后临床缓解情况的独立预测指标，但可能不适用于OS的预测。

Abstract

Objective

To explore the value of neutrophil lymphocyte ratio (NLR) in predicting the efficacy of neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (ESCC).

Methods

Clinical data of 104 patients (92 males and 12 females) with esophageal squamous cell carcinoma undergoing preoperative neoadjuvant therapy in our center from January 2016 to June 2020 were collected and analyzed. Blood routine test was carried out in 3 d before neoadjuvant chemoradiotherapy

including neutrophil count

lymphocyte count

monocyte count and platelet count. Then NLR

platelet lymphocyte ratio (PLR) and lymphocyte monocyte ratio (LMR) were calculated respectively. Iodine water radiography and chest enhanced CT scanning were carried out before and after neoadjuvant treatment

so as to determine the regression grade of tumor. The survival status of all patients was followed up for 4~53 months. Mann Whitney

test was used to analyze the difference of continuous variables between groups. Receiver operating characteristic (ROC) curve was applied to evaluate the predictive effect and the best cut-off value of NLR.

Chi-

square test was performed to analyze the correlation between NLR and clinical characteristics. Logistic regression and Cox regression analyses were a

dopted respectively to investigate the independent predictors of neoadjuvant remission as well as the independent prognostic factors of overall survival (OS).

Results

Among the 104 enrolled patients

there were 0

54 and 12 cases who achieved complete remission (CR)

partial remission (PR)

stable disease (SD) and progression disease (PD) criteria respectively after neoadjuvant therapy. NLR before treatment was revealed to be an independent predictor of neoadjuvant chemoradiotherapy remission (

=0.404

95%

: 0.208~0.787

=0.008). ROC curve showed that NLR had a moderate predictive effect on neoadjuvant chemoradiotherapy remission (AUC=0.737

95%

: 0.631~0.844

0.001)

and the optimal cut-off value was 2.77

with the corresponding sensitivity and specificity of 0.712 and 0.737

respectively. However

multivariate Cox regression analysis showed that only surgery following neoadjuvant therapy was an independent prognostic factor for OS (

=0.258

95%

: 0.068~0.983

=0.047).

Conclusion

NLR before treatment may be an independent predictor of clinical remission after neoadjuvant therapy for ESCC patients

but it may not be suitable for OS prediction.

关键词

Keywords

references

左婷婷, 郑荣寿, 曾红梅, 等.中国食管癌发病状况与趋势分析[J].中华肿瘤杂志, 2016, 38(9): 703-708. DOI: 10.3760/cma.j.issn.0253-3766.2016.09.013.

ZUO T T, ZHENG R S, ZENG H M, et al . Incidence and trend analysis of esophageal cancer in China[J ] . Chin J Oncol, 2016, 38(9): 703-708. DOI: 10.3760/cma.j.issn.0253-3766.2016.09.013.

张思维, 郑荣寿, 左婷婷, 等.中国食管癌死亡状况和生存分析[J].中华肿瘤杂志, 2016, 38(9): 709-715. DOI: 10.3760/cma.j.issn. 0253-3766. 2016.09.014.

ZHANG S W, ZHENG R S, ZUO T T, et al . Mortality and survival analysis of esophageal cancer in China[J ] . Chin J Oncol, 2016, 38(9): 709-715. DOI: 10.3760/cma.j.issn. 0253-3766. 2016.09.014.

CHEN W, ZHENG R, BAADE P D, et al . Cancer statistics in China, 2015[J ] . CA Cancer J Clin, 2016, 66(2): 115-132. DOI: 10.3322/caac.21338.

SHAPIRO J, VAN LANSCHOT J J B, HULSHOF M C C M, et al . Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial[J ] . Lancet Oncol, 2015, 16(9): 1090-1098. DOI: 10.10 16/S1470-2045(15)00040-6.

ANVARI K, ALEDAVOOD S A, TOUSSI M S, et al . A clinical trial of neoadjuvant concurrent chemoradiotherapy followed by resection for esophageal carcinoma[J ] . J Res Med Sci, 2015, 20(8): 751-756. DOI: 10.4103/1735-1995.168377.

LIN J W, HSU C P, YEH H L, et al . The impact of pathological complete response after neoadjuvant chemoradiotherapy in locally advanced squamous cell carcinoma of esophagus[J ] . J Chin Med Assoc, 2018, 81(1): 18-24. DOI: 10.1016/j.jcma.2017.08.007.

LI K J, XIA X F, SU M, et al . Predictive value of lymphocyte-to-monocyte ratio (LMR) and neutrophil-to-lymphocyte ratio (NLR) in patients with oesophageal cancer undergoing concurrent chemoradiotherapy[J ] . BMC Cancer, 2019, 19(1): 1004. DOI: 10.1186/s12885-019-6157-4.

LIN C Y, KWON H, RANGEL RIVERA G O, et al . Sex differences in using systemic inflammatory markers to prognosticate patients with head and neck squamous cell carcinoma[J ] . Cancer Epidemiol Biomarkers Prev, 2018, 27(10): 1176-1185. DOI: 10.1158/1055-9965.epi-18-0408.

MATEU-JIMENEZ M, CURULL V, PIJUAN L, et al . Systemic and tumor Th1 and Th2 inflammatory profile and macrophages in lung cancer: influence of underlying chronic respiratory disease[J ] . J Thorac Oncol, 2017, 12(2): 235-248. DOI: 10.1016/j.jtho.2016.09.137.

DUDANI S, MARGINEAN H, TANG P A, et al . Neutrophil- to-lymphocyte and platelet-to-lymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation[J ] . BMC Cancer, 2019, 19(1): 664. DOI: 10.1186/s12885-019-5892-x.

LI A, HE K, GUO D, et al . Pretreatment blood biomarkers predict pathologic responses to neo-CRT in patients with locally advanced rectal cancer[J ] . Future Oncol, 2019, 15(28): 3233-3242. DOI: 10.2217/fon-2019-0389.

EISENHAUER E A, THERASSE P, BOGAERTS J, et al . New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)[J ] . Eur J Cancer, 2009, 45(2): 228-247. DOI: 10.1016/j.ejca.2008.10.026.

YANG H, LIU H, CHEN Y, et al . Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase Ⅲ multicenter, randomized, open-label clinical trial[J ] . J Clin Oncol, 2018, 36(27): 2796-2803. DOI: 10.1200/jc o.2018.79.1483.

YODYING H, MATSUDA A, MIYASHITA M, et al . Prognostic significance of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in oncologic outcomes of esophageal cancer: a systematic review and meta-analysis[J ] . Ann Surg Oncol, 2016, 23(2): 646-654. DOI: 10.1245/s10434-015-4869-5.

ETHIER J L, DESAUTELS D, TEMPLETON A, et al . Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis[J ] . Breast Cancer Res, 2017, 19(1): 2. DOI: 10.1186/s13058-016-0794-1.

BRUIX J, CHENG A L, MEINHARDT G, et al . Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase Ⅲ studies[J ] . J Hepatol, 2017, 67(5): 999-1008. DOI: 10.1016/j.jhep.2017.06.026.

COFFELT S B, KERSTEN K, DOORNEBAL C W, et al . IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis[J ] . Nature, 2015, 522(7556): 345-348. DOI: 10.1038/nature14282.

WANG S M, CHEN F Y, TANG L L. IL-32 promotes breast cancer cell growth and invasiveness[J]. Oncol Lett, 2015, 9(1): 305-307. DOI: 10.3892/ol.2014.2641.

KIM T G, PARK W, KIM H, et al . Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in rectal cancer patients following neoadjuvant chemoradiotherapy[J ] . Tumori, 2019, 105(5): 434-440. DOI: 10.1177/0300891618792476.

HASEGAWA S, EGUCHI H, TOMOKUNI A, et al . Pre-treatment neutrophil to lymphocyte ratio as a predictive marker for pathological response to preoperative chemoradiotherapy in pancreatic cancer[J ] . Oncol Lett, 2016, 11(2): 1560-1566. DOI: 10.3892/ol.2015.4057.

TEMPLETON A J, MCNAMARA M G, ŠERUGA B, et al . Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis[J ] . J Natl Cancer Inst, 2014, 106(6): 1-11. DOI: 10.1093/jnci/dju124.

ZHANG H, LI Z L, YE S B, et al . Myeloid-derived suppressor cells inhibit T cell proliferation in human extranodal NK/T cell lymphoma: a novel prognostic indicator[J ] . Cancer Immunol Immunother, 2015, 64(12): 1587-1599. DOI: 10.1007/s00262-015-1765-6.

VAN DER WINDT D J, SUD V, ZHANG H, et al . Neutrophil extracellular traps promote inflammation and development of hepatocellular carcinoma in nonalcoholic steatohepatitis[J ] . Hepatology, 2018, 68(4): 1347-1360. DOI: 10.1002/hep.29914.

RICE C M, DAVIES L C, SUBLESKI J J, et al . Tumour-elicited neutrophils engage mitochondrial metabolism to circumvent nutrient limitations and maintain immune suppression[J ] . Nat Commun, 2018, 9(1): 5099. DOI: 10.1038/s41467-018-07505-2.

JUNG Y J, ISAACS J S, LEE S, et al . IL-1β mediated up-regulation of HIF-lα via an NFkB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis[J ] . FASEB J, 2003, 17(14): 1-22. DOI: 10.1096/fj.03-0329fje.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Construction of machine learning-based prognostic model of centrosome amplification-related genes for esophageal squamous cell carcinoma

Knock-down of long non-coding RNA GK-IT1 inhibits proliferation and promotes apoptosis in esophageal carcinoma cells

Correlation of XRCC1 Arg399Gln polymorphisms with prognosis of esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy

Expression of AZGP1 protein and its relationship with prognosis in esophageal squamous cell carcinoma

Correlation of copy number variation of Variation_91720 in PIK3CA gene with susceptibility of esophageal squamous cell carcinoma: a report of 149 patients from Southwest China

Related Author

ZHENG Hongliang

HUANG Ping

YANG Huan

BAI Jianying

LI Chaoqun

Li CHEN

Xin YANG

刘岩海

Related Institution

Department of Gastroenterology， Second Affiliated Hospital， Army Medical University （Third Military Medical University）

Department of Cardiothoracic Surgery, the First Affiliated Hospital of Chongqing Medical University

⁰